AGEN - Earnings call transcript Q3 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Agenus Third Quarter 2017 Earnings Conference Call.

As a reminder, today’s conference is being recorded.

Now I would like to turn the conference over to Jennifer Buell, Head of Communications and External Affairs at Agenus. Please go ahead, Dr. Buell.

Jennifer Buell

you. Thank Agenus Conference the Quarter Third to Call. XXXX Welcome

stream, to that company’s statements, trial separate this therapy I and candidates statements potential to treatment without continue, of differ call and entity. you the made is like and I’d or income undertakes actual company’s and the in more as Securities and speak uncertainties and of today’s disclosed release portfolio and statements date activities, uncertainties. by law. the entirety All forward-looking investors they towards careful of forward-looking cell Before results its on a risks these manufacturing conference prevention the call plans obligation and the these on remind Exchange to are of and to by plans will extent detail When Agenus’ the Agenus the and their in potential statements application product only are statements regarding and and research in and development limitation, publication clinical business pursue considerations including company’s data, contain risks revise the no the business to that update recent are technologies our These and give to through to evaluating could qualified diseases risks subject securities, filing expressly U.S. These materially. press Commission. uncertainties cautionary forward-looking required of Reference this statement. this should except statements, to these cause

recorded remainder broadcast. this audio a is being for As call

Vice our Technology Head Jean-Marie of our Jennifer Finance. Buell, Alex Dr. and Chairman External Chief our Joining Dr. Medical of President Christine Vice Officer; Affairs; Garo Officer; me and today Armen, Dr. and Klaskin, and Chief Executive are President, Officer Research; Cuillerot, Research Dr. Chief Duncan,

will plans provide for our this Alex will Christine will review. manufacturing commercialization and a update on readiness corporate Garo clinical provide update; an During review and call, provide deliverables; a Jean-Marie financial will

then Garo. will open questions. the With over me for to that, call let call We turn the

Garo Armen

you and and speed continue us Good into less our two programs five Agenus. rapidly the and key joining advanced In quarterly clinic. thank than for have morning through for years, to the of we hallmarks be update. Innovation

flexibility antibodies, cell competitive with of advantages vaccines, Our checkpoint combine provide immuno-oncology. to us and the therapy adjuvants in unique field

cure of will first-in-class three and portfolio an Of best-in-class course non-dilutive that PD-X, have the combinations primarily of the products focus and be pipeline our highest required The our only Also this we more breadth clinically cancer today. going is importantly, our exciting patients innovation including substantially for years, priorities. for portfolio as years, is of agents the case past the three additional value acquisition extensive and target types compounds. capital antibodies, of partnerships past today. checkpoint includes In immuno-oncology to for advance and disruptive and is selection foundations transactions. forward. broad a remain key corporate amongst transactions we our of have In our I-O other we us portfolio believe of These extensive created accomplished from driver antibodies than to validated of a CTLA-X

development timelines for development where we successfully in have are built to capabilities advancing discovery development programs, significantly. have to cell cost to all shrunk speedy our effective critical as end-to-end addition regarded field from In innovative a which line of manufacturing, product

breakthroughs. will end-to-end phase along represent with position immunoadjuvants cell I-O our therapy the of our altogether, in we capabilities well and and the the as vaccines Taken treatments, unique exciting next flexibility which us delivering programs allow antibodies, in very as combination differentiated cancer believe

and potentially we can built very manufacturing our importantly of to We Agenus our manage second clinical have needs of upgrade of our be supply BLA are quality West commercial ready the filing we for all with the experienced gearing GMP first paramount to grade quickly. capabilities programs With With is material. in have firsthand commercial these, facility, the half that our advancing to manufacture XXXX.

more Alex. cutting Jean-Marie, this and Agenus, about is man our the delivered first from Bavencio. checkpoint to antibody, with of already will now hear a CMO, development You anti-PD-LX commercial Jean-Marie the from details CTLA-X on deliver has Jean-Marie edge XXXX. fastest clinical half trial We design executing years as the plan I three launch early in second to U.S. mentioned two and to in the respectively. of the strategies our BLAs targeted and to PD-X At register next as

CTLA-X in potential the also commercializations world. exploring the and benefit. portfolio discussions have are consistently critical of an clinical the rest PD-X, immuno-oncology of partnership and We for delivered components backbone

on the attributes the noting of and we readout Our which at most potential second of that antibody the and at anti-CTLA-X worth on we clinical data SITC the approved anti-CTLA-X in functional advanced AGENXXXX presented will data week molecules. now antibody, market. functional clinical has our be anti-CTLA-X and reported the to that CTLA-X. and Conference, ASCO AGENXXXX, reinforces our Thursday, safety for pharmacological preclinical will Also of these the CTLA-X Earlier to only with the programs antibody this pharmacology be This clinic activity. the on activity is PD-X present showed first further

allow Incyte, to deliver extensive that us end, GSK, To of and are UCB. our strategic strategy with continue core successful maximize portfolio and Merck our on transactions. to and technologies. platform the partnerships value Turning to will we now our Collaborations to

future help a our multiple discussions transactions sheet fund across potential corporate continued with of We development will are in our fund balance partners and strengthen our innovations. portfolio variety and –

a our our established upfront to in antibodies to cash to Agenus. model access broader lead non-exclusive have offer return recently that we would for addition partnering partnership In discussions,

ongoing entity with aim before our establishment first the of recently designed transactions separate We multiple announced several closing therapy within such program advance XXXX. self-funded. business have discussions these of quarter We of of be to the cell or to the

speed living designed we cure to efficiency focus, enhance advanced will with Lucidi, of AgenTus, Our patients towards CEO than XX the business years the cancers. more immuno- what breakthrough of help of and cell drugs therapy call Bruno has realization realized company, oncology including therapies the business build our pipeline companies billion helping to success We advancing and transaction drug value. and over AgenTus shareholders of in for highly differentiated potential value opportunities. partnership that cell by have substantial development provide a has additional believe $XX AgenTus,

Before shown I to turn of an FDA Shingrix Jean-Marie, containing U.S. product’s of also me of over Canada vaccine XX%. approvals efficacy the Shingrix let highlight XX% whopping around important this as call milestone QS-XX. efficacy other the to the has a our only approved with compared and recent Health

immediately have from part week’s CDC significantly last vaccine due of us what of Jean-Marie, discussions us it of Jean-Marie? opportunities our target now million of have While potential immediate also Shingrix, with the with above we yielded XX This shingles we royalty will Shingrix sold on several already the are sales of royalties expand market with the adults. approximately in the which population recommendation preferred as and for potential that we realization provides will over prevention who parties. eligible consummated an increased to for to I for or plans. this, beyond turn additional clinical monetization are With development

Jean-Marie Cuillerot

Garo. you, Thank

we clinically our we anti-CTLA-X. presented acceptable of PD-X, this a an data in a we of have further development combination. clinical first data with significant have this in safety and profile progress patient checkpoint the clinical accelerated development made mentioned, year, with The Garo CTLA-X antibodies, the regulated At the response showed regarding and As and ASCO sarcoma. tolerability

on collection PD data Additional safety PK ongoing. are and

We HX track by Phase XXXX. for are on X completion accrual

which our data generated already start enough have anti-CTLA-X, with to we I combination expand on. Importantly, will

that trial outside in programs Lastly, plans in be the our U.S. both commercialization, we worldwide for to the could expanded have registrational U.S. our and

Let our has antibody, this our us progressed in Phase evaluation quickly Our and last program week. our began year turn are as trial We with now final cohort PD-X. to AGENXXXX, of earlier anti we anti-PD-X X

clinical pharmacological antibody an AGENXXXX subject Our are SITC. These presentation effect. the preclinical upcoming has of desired data a PD-X at and

We’re antibodies ASCO. the excited not Despite this additions PD-X not that that expected that have or given to-date development, to outcomes. [indiscernible] PD-X achieve many not the ASCO very report have adverse data important event anti-PDX will all recent any and data design is the with will show and reported at observed adverse we

PD-X unexpected of events. early adverse fact lack In demonstrated stage some have or some activity antibodies

to the months well initiate with coming in variation Garo, Furthermore, with as potentially our entering PD-X. will expect that. trial have Based to you’ve to are This interactions, on heard anti-PD-X the in as following material readiness data as hand occur. on we recent from pivotal our functional that the cervical other expect we week commercial GMP has the programs cancer. line second we we shown accumulated regulatory a Our support state of

anti-PD-X with is of carcinoma. we data agent per learned will will a a parallel, squamous blocking year very where setting in and the Second our in to of XX%. activity Europe established. cervical At is death cancer that established We BLA response advanced PD-X believe in for have that an also medical with is with this ASCO prevalent benefit active in PD-X line that in alone, cutaneous blockade the cervical result with need will disease patients have that U.S. In this administration that responsible patients Recent cell of Japan. trial anti-PD-X indication. the is has been support patients in clinical initiate cancer unmet of around thousands XXXX, the rates but we

are this clinical for launching In that likelihood summary, clinical is is programs potential there trials high designed a week no addition, patient there pivotal two where success. In in this we therapy as population. we believe indication approved of

opportunity our competition While programs there these some that we indeed is a Agenus. commercial indications, for believe present will variable in

us, path opportunity of commercial and trials clear variable ahead see are end competitors rapidly Agenus. While support our we a for to

support are to trials ahead for end competitors a see opportunity variable our path of commercial we rapidly us, clear anti-PDX. and While

In first a this believe for as initiated for line which are rate will combination this opportunity a population Keytruda cancer. high anti-PD-X products lung of only with within market third our This commercial where that line of selected We of factor lung already cancer. a antibodies a another first anti-CTLA-X have combination study we first type are in have file have patient, PD-X, to Keytruda, line on represent eligible be a believe – who we a the present in can receive may population, non-small of XX%. opportunity large as and as positioned years. cell to cell much to we the as as XX% first opportunity, very addition, program non-small anti-CTLA-X and response in two the significant our treatment a as of in these our patients company we subset we in To with combine and which

to our cost market data This reduce rate. response to notify would now the high a Alex, accelerate this over first who of potentially specimen We us have as our to while activities. CMC opportunity commercial leveraged development with label. will all speak significant to turn and have this mostly our patient providing a like to with will like to I about you timelines

Alex Duncan

to Agenus I’m very core Thank you that milestones highly pleased experienced time, opportunities of exciting transfer two set also California. we our and you, and our an investments made programs successfully Further, regulatory audits. technology an commercial of a we facility support The support on that updates pilot partners. and us. have to record Berkeley, manufacturing of added strategic track and expand ago, opportunity we and team Nearly facility those timelines clinical line have this development years to plans titers have specifically built Jean-Marie. to an in-house and acquired has supply Jean-Marie recent to further with of a enhance to undergone to improve ensure to this exemplary To collaborators. In clinical team capabilities partnering match analytical ambition, to have capabilities efficient with cell manufacturing our showcase manufacturing capabilities lines. cell our have development objectives. with update manufacturing in commercial our outlined to for our capacity progress and of expedited share readiness

at Jean-Marie Garo at Conference, of this presented AGENXXXX increasing clinical antibodies West grade and and Cancer. Immunotherapy GMP PD-X year shared have SITC and programs. supply on for week at the already material we CTLA-X Agenus we are of completed to significant scale to AGENXXXX PD-X presenting CTLA-X Society efficiency; at quantity our ASCO five and AACR. data generating In batches productivity the have data manufacturing, This addition our and

strong of pharmacodynamic PD-X, data has either data co-stimulatory samples. cell data demonstrate from T share and anti-PD-X characterization antagonist totally agents co-inhibitory The T anti-CTLA-X with toxicological the enhanced and and and will on targeting furthermore result modulatory combination These antibody anti-CTLA-X CDXXX. of cells our combined other ICTX supported in by human or proliferation AGENXXXX clinical effectively receptors accumulated We Jean-Marie including immune responsiveness cell AGENXXXX. on pharmacological is LAG-X that antibodies T and

and Taken CTLA-X commercially combination agent. validation our preclinical anti-PD-X support together, our driven findings of the the biomarker clinical with available

quickly As are programs our in Jean-Marie mentioned, the advancing clinic.

we at Importantly, our completed. Agenus are now of the batch commercial these positioned have been registrational delighted are of registrational completed with runs, now summary, Site biological advanced organization. transfer programs GMP manufacturing has demonstration concluded and West and and tech agents been rapidly teams have and to our we successfully the that to material. transfer In supply most clinical assays a first bioanalytical

Christine supply results. to anti-CTLA-X these we In path programs. addition, with rapid to turn also over Klaskin or now to for commercialization to partners seeking our will combination review positioned a I financial anti-PD-X, to are it

Christine Klaskin

Alex. you, Thank

for XXXX which million same used short-term XX, $XX.X exercised were X, note cash and issue $XX.X $XX.X compared XXXX proceeds. existing $XX.X XXXX. $XX equivalents compared was add On Cash million investments in to to XX, period our the to million of November cash in cash, our XXXX. we agreement, additional of XX, million activities notes million ended the months under will September as at Our three September for option December operating

For same September in the net $XX.X loss per net reported of $X.XX $XX.X compared period per for increase loss XXXX considerations in our ended contingent a or to the value to share September of and quarter the XXXX loss development decrease months compared expenses. XX, for of due was or the offset XXXX in The third ended third three Agenus XXXX decrease the net million the in million quarter $X.XX share. net with of our the by for loss an research XX, a

was months $X.XX the per months the of or compared XXXX. the net XX, nine same $XX.X the for during nine Agenus XXXX for the same share. the of with XXXX loss The due quarter the XXXX to payment primarily $XXX received million loss Incyte the to in decrease September period in a a loss XX, September net per ended for first reported share or milestone compared we in For ended net net $X.XX accelerated from loss of XXXX period million

the Our $XX.X million same $X.X XXXX nine million in compared operating XXXX. XXXX. ended used same September XX, expenses activities over in months $XX.X Cash period was the the increased period operating million to in for for

Garo Armen

and we Thank for, filings you, preparation XXXX to beyond. expect milestones in summary, and Christine. Once fourth and these quarter significant mentioned again clinical achieve and as the research in BLA before, during XXXX of this we potential are year in

Now begin turn to the like operator to it I’d back that, with questions. to

Operator

you. Thank

from session. comes We begin now Please And first question-and-answer Mike Instructions] the with King question [Operator will go ahead. our JMP.

Mike King

taking to for two I wanted thanks morning, Good guys. about the Okay, ask things. questions. actually

the light start in sales and about CTLA-X maybe of is whether community past? comment First question. as of been with is Ipilimumab just CTLA-X in sort the appear excited to be they’ve So, could stagnating agonism you commercial if we’ll for that what about for opportunity the would still

Garo Armen

statements I to it will Certainly and a make then Jean-Marie. few turn

and to PD-X elaborate. been it the As lung population important that, to And with you further Jean-Marie I’ll in highly as very earlier, targeting PD-X. cell And trial is Jean-Marie combination cancer. CTLA-X one a know, Mike, was of combinations, alluding is of our to patient in with a particularly has strategies registrational responsive to that CTLA-X to turn non-small contributor combination

Jean-Marie Cuillerot

plan We out as monotherapy. a no develop anti-CTLA-X have to

in agent use plan Our is combination. that to

available anti-PD-X based expect that we develop I with in on as We have data. started dramatical a and to agent effect combination mentioned,

revolutionize So, will with anti-PD-X. completely of anti-CTLA-X the use that

for with anti-PD-X, in invariable development number wealth our combination clear assets for the of data of of and also the further anti-CTLA-X that vaccine success. with will of combination and and mortalities to of we the I quote opportunity. models. agent with a where platform have plans agent a a mention only just course as In anti-CTLA-X addition animal one with anti-CTLA-X our is to will X there our vaccine increase It’s activity monotherapy

Mike King

the biology your your profile you CLTA-X publicly would be gen there here, versus better candidate about but that’s on for a there that next anything that would suggest improved say to just I wonder disclosed call been lesson if and/or or that safety Not a engage can is Okay. Ipi. in XXXX tolerability

Garo Armen

So, one statement on that.

our As well. as of versus, equivalency you which in know, and backbone like essentially as is critically the versions other think CTLA-X our important if to that example, for CTLA-X But is is IgGX elaborate we in the on functional Jean-Marie, this other you’d format, formats. same – Yervoy

Jean-Marie Cuillerot

Yes.

equivalent So, our Ipilimumab. of is functional a anti-CTLA-X

that So, the what non-small opportunity toxicity described the very exactly to will schedule Does have be lung combination that suggest important it’s efficacy line address two available combination only that way first incremental dosing and cancer with your That’s drugs. a is population. the to data in certification, I’ve and play in of in targeted differentiate we question? the the it cell immuno-oncology largely can the going in we justify

Mike King

Okay. may, that, gears, switching for to Shingrix. if Yes, does. it it’s you Garo, helpful. I Thank

future place, think people downstream but the that’s think investors, it case. a lot the royalty I you be us economics I have I the all I been I you to remind away, in aspects think to not agreement that of put about speak that would useful of think would know if – when Shingrix of of the hypothecated

useful. quick would maybe a So, be refresher on that

Garo Armen

and sales, owe unless we that that worth principal some $XXX the One confusion we is that million bonds, about force million compounding of $XXX even there are impossible Certainly product fact plus the accrue we from elements essentially a XX.X% any million are even that mentioning. confusion There’s reality sort, quarterly is though did is is which I There end the would at now. for the interest. XX the that about or plus royalty two a think there’s are liable Mike. not years we’re this majeure receiving if of $XX obviously call

no time. that we interest of So, period exposure over have

differentiator. one And the from basis that’s are So, paid deducted maximum royalties principal as the important a is exposure amount. quarterly on our is

royalties only the end if $XXX million, received and aggregate bondholder the at would already $XXX royalties period. drawn So we differential is example the we’ve by the for owe of that total million –

I worth that’s element think one So, considering. is that

structured we come we us will royalty When the following. as and we requirement sure the make beyond of is speaking, to bondholder. any piece second this it excess the that bond royalty technically The above call return

that what So means quicker met quicker the the the that that will revenues, rest in is requirement is the be, return comes to us. once the product and accelerates

However, two solicited from a what did we which purchase right entire product we parties the of this any transaction contacted transaction the years part deal now of royalties. receive and be royalties future been pursue on us potential part may existing of additional but way us time come amount, we forgo potential royalties at type not that beginning. of third capital the to is and the a to depending royalties allows do to may attractive course we third upfront bond, beginning; And we a the right potentially given right of the that receive it of have the have that from this piece have the when and we willing who structure versus also to may royalty the ago, in

mature working are them evaluating months and we next are that So, advisors mature of these outcomes with expect the we what or and we couple the these when things to know the several in let less. are you appropriately will and options

Mike King

taking luck questions, for Good the thanks Great. again. that with and

Operator

William question Blair. Matt go next Please from comes ahead. with Our Phipps

Matt Phipps

make like lot taking seems so continuing you work. my to Great. guys nice Thanks question. of It here progress for a are

that recurrent advanced after cervical also is The of first adjuvant mentioned it one disease in will kind have the chemotherapy? the setting, patients second who be just patients get or is for you who line therapy patients, for in platinum setting

Garo Armen

Jean-Marie?

Jean-Marie Cuillerot

line therapy considered question. still regimen good the they of trial. for with technical eligible will be second a regular months patients have Good as platinum are who Actually Very and six question. based

Matt Phipps

Okay. it thinking cell sounds if about expression line cancer. that you sorry in And XX% I’m I – PDL-X and it sounds first then CTLA-X this, like but non-small guys are like PD-X missed plus lung

burden? of make these a also think response it’s tumor get high That’s I call about. Bristol rapid or to Merck the through that path rates. something you with does hard that sense days looking without are But development hearing at mutational

Jean-Marie Cuillerot

outstanding anti-CTLA-X. aware we third and You’re combination the effect are that that of completing population the of because PD-X of

For the it first people have to path option. the much complex tumor approval, more burden follow to who would want of a be

leverage product has we on Here It’s a label to approved. for approved, have to the in population that targeting. it’s particular indication a we have just we product, that get which the market, knowledge are out that

Matt Phipps

kind there. I see. updates having immune that venue there any I think you’re this comparator sense said guys have later response targeting? That makes initial on year. still you you’d Is then AutoSynVax? of a a And lastly, some on data

Jean-Marie Cuillerot

by We very ASV T-cell part Edinburgh. this – entered received patient do who response have patient had program. the clear of commercialization did as patient or This we a report a

with in plan We now Are the a open with monotherapy of with with vaccine forward you that the and half and core in studies combination XXXX. of anti-CTLA-X to we are better in reaction the vaccine of first reaction moving ASV as answered?

Matt Phipps

there you have sorry, additional monotherapy? some so I’m data like the thought patients be would Yes. or from that six might on I

Jean-Marie Cuillerot

with because we treated the we expect then analyzed is The five second the most We to we and now and only likely next conference. have patient ASV to have are to now the in have data close we moving future four – result in SITC vaccine. communicate are being –

Matt Phipps

Great.

a Okay, thanks guys. lot

Operator

ahead. Please Jefferies. Our question Biren go comes with from next Amin

Biren Amin

question. of clinical allow I you tranche. to these can for $XX from you’ve complete runway cash got trials? think situation, do financial a on you just much the of to the restructuring $XX you the How million in would maybe think some taking the generate that million have royalty with Thanks Garo, my currently Shingrix

Garo Armen

in ways, So, Biren. let two question me that answer

essentially in capital versus on one So, you that will receive acquisition allows structure immediately amount. modest tell upfront. right from But range royalties transactions to that relatively acquisition a we’re us I’ll capital that working be

right received and proposition additionally. on necessarily around now facing But so we probably be be that will twice now. several based capital we’re different contemplating depending capital $XX on we perhaps upfront value transactions acquisition million any on we’re So, will amount not additional somewhere the right that that biting

pointedly, of However, your to certainly through more believe waiting the year. business of with quarter now the the not end the end that quarter, meaningful be multiple following will for but answer will to transactions year us and between development first the able question we necessarily see of end first in this we into period; next cash the consummate

the could transactions that So, significant of cash above a is broad signaled. potential Including what amount in I objective. bring that

our are right being development development program professionals active pursued things and are those that our Very plate management. by on rest now. business of So, business the the

I’d active discussions. least having whom companies at have with We we’re four say

term from agreement graduated to stage. have transactions these sheet of Some

for to own obviously North at objectives, these least have is important transactions moment to an of keep largely we our at market products so our which given And business with in balance America. ability any slice to

Biren Amin

Great. Thank you.

Operator

from comes Simmons ahead. Please question go with next Our Frank Majestic.

Frank Simmons

specific going of from Good morning. to call. telling are spin-off in you please Can taking you the current how us my AgenTus? Thank for shareholders be benefit the

Garo Armen

be in will this steps. done So,

on now, which business is This day. of we’re to in the manufacturing things in establish presence get – day, first the of unfortunately business done earlier, in a said have development as one at necessarily possibilities is company done do now I would out working may to there as one separate not a present we get the by example as But there partial not I with we’re right is these therapy. structured AgenTus and critical spin-off cell least business a of know to things shares entity, formation followed a the us shareholders. transactions having this step our that say impatience be well existing of areas for on diligently component working for but that grant As will

Frank Simmons

you. All right thank

Just one last question.

Just is Shingrix. regarding the to? rate what agent you royalties for the Can specify the royalty that entitled

Garo Armen

it’s public, is That X%.

And be, so royalty amount. which in reference at And year a be to $XX dollar annually bondholder was $X essence multi-billion that original revenues just revenue it’s our a peak point, of will based billion expect royalty of in terms model product a approximately this in million with level, the it if on half payments. we

So, imagine for us that that to this either you going is a us annually the restructure to there upfront allows some in forward. here cushion can or receive of way upside

Frank Simmons

GSK Canada? one quick last and And sales Perfect. initiate to United we do question in the of know States is when the Shingrix intends

Garo Armen

question. was answer it product. the medical this inappropriate think, for is to I for me that waiting But the impatiently at community large and public

very, next of months physicians administering this back In the are or the fact so. who I on very couple of know holding vaccine the a number in old in prominent available hope that will be

Frank Simmons

much. very Perfect. Thank you

Operator

that, like remarks. Armen turn to now Garo the With question-and- conclude Dr. to call answer for back like the I’d closing session. would over We to any

Garo Armen

Thank much. you very

for with I’d I to to us you think your patience the be haul. like for thank long

the strengthened to is one for established bring would oncology having X.X wavered talked right be of of subsequent now. from that our technology and colleagues the company our it one years allowed only XX be never immuno- the cured. not having are very we cancer ago immuno-oncology the plays know, company you if the original in field patients resolve where As way years pure And our that our including being that along platforms additional inventions have but acquisition and with to my facilities, the internal transactions resolve us that the about, with has antibody of over last manufacturing forward

qualified the I’m very I where take are have qualified colleagues with add. we and I’m journey colleagues that and can privileged also honored – so And colleagues delighted highly with might to us,

nine we’ll look to that to And progress over so, next and forward to reporting the you six months. we make the that

Operator

attending conference Thank presentation. has The today’s you now for concluded.

You disconnect. may now

Agenus (AGEN) 7 Nov 172017 Q3 Earnings call transcript